Brookfield Infrastructure Partners capped a strong 2025 with double-digit FFO growth, a record capital recycling program, and a raised distribution. Management highlighted a massive, disciplined expansion in data infrastructure to meet AI-driven demand, forecasting a return to 10%+ growth targets.
The alternative investment giant reported its strongest annual results in four decades, fueled by a surge in fundraising to $240 billion. Executives pointed to early signs of a reopening in deal activity and IPO markets, setting the stage for increased asset sales in 2026.
Brunswick Corporation (NYSE: BC) closed its 2025 fiscal year on a confident note, citing a resilient recovery in the marine market, a historic surge in free cash flow, and significant debt reduction. While navigating persistent tariff headwinds, the company's leadership pointed to stabilizing retail demand and strategic market share gains as key drivers for cautious optimism heading into 2026.
Axis Capital (AXS) reported robust 2025 results, marked by record premiums and its best underwriting performance in over a decade. While outlining a confident growth trajectory, executives struck a cautious note on cyber insurance and reinsurance headwinds for the coming year.
British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.
As a profitable outlier in a battered sector, Ethos Technologies' successful IPO marks a pivotal test for investor appetite in 2026's tech listings, even as its debut valuation reflects a more sober market reality.
With his term winding down, Federal Reserve Chair Jerome Powell offered rare, pointed advice to his eventual successor during a recent press conference, emphasizing the imperative of maintaining the central bank's independence from political influence.
In a turbulent session driven by geopolitical fears, gold staged a historic V-shaped recovery while Bitcoin languished, raising fresh questions about the cryptocurrency's viability as a modern safe haven.
Shares of Viavi Solutions soared over 17% after the network test and measurement company posted fiscal Q2 results that smashed analyst expectations, fueled by robust demand from data center and aerospace clients.
While the broader ASX has climbed nearly 10% over the past year, shareholders of cloud accounting giant Xero have watched their holdings plummet by 47%. This stark divergence raises questions about market sentiment versus the company's underlying performance, which shows surprising resilience.
The defense giant's stock jumped over 4% following an optimistic sales forecast and a major new agreement to significantly boost production of a key missile defense system for the U.S. military.
Canadian Pacific Kansas City's mixed Q4 results and 2026 outlook have sparked a tug-of-war between short-term optimism and longer-term concerns, as a new share repurchase program clashes with a year of declining shareholder returns.
Following its strategic rebrand from SMART Global Holdings, Penguin Solutions (PENG) is positioning itself at the forefront of AI and high-performance computing infrastructure. Yet, its stock tells a complex story of short-term volatility against long-term potential, raising questions about its true valuation in a heated market.
Cardinal Health (CAH) stock has drawn renewed investor interest following robust financial results, with revenue topping $234 billion and net income near $1.6 billion. The healthcare distributor's shares have rallied over 66% in the past year, though its premium valuation compared to peers is sparking debate among analysts.
Coty Inc.'s shares have tumbled nearly 60% over the past year, trading at a steep discount to industry peers. While a discounted cash flow model suggests significant undervaluation, the prolonged weakness raises questions about the cosmetics giant's turnaround narrative and whether the market is missing a hidden gem.
The Malaysian software firm AppAsia Berhad (KLSE:APPASIA) is showing signs of a sustainable recovery, with key profitability metrics turning positive after years of struggle. Investors are taking note as the company begins to generate returns from reinvested capital.
As XPeng shares face sustained pressure, a deep dive into its valuation reveals a stark contradiction: while a fundamental cash flow model suggests significant upside, market-based metrics paint a more cautious picture. We analyze the numbers behind the divergence.
The U.S. dollar extended its weekly decline as fresh geopolitical risks, including new tariff threats over Cuba and potential military action against Iran, dampened appetite for American assets, despite domestic political relief.
Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.
As Western Digital prepares to report its fiscal Q2 2026 results and host a key Innovation Day, investors are watching to see if the company's product roadmap and market commentary can justify its soaring stock price and meet burgeoning AI-driven storage demand.
